Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group

Table 3 Font trial: outcomes by treatment arm

The co-primary endpoints included: (1) Reduction in proteinuria at 6 months by ≥ 50 % of the value at the time of screening, AND (2) Estimated GFR (eGFR) at 6 months ≥ 75 % of the value at the time of randomization in those with an initial eGFR <75 mL/min/1.73 m² OR eGFR persistently ≥75 mL/min/1.73 m² in those whose renal function was ≥75 mL/min/1.73 m² at the time of randomization

ISSN: 1471-2369